Status	Stage
New Updated	Protocol Review

• 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
• 5-alpha-reductase inhibitors for prostate cancer prevention
• Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
• Adjuvant chemotherapy for invasive bladder cancer (individual patient data)
• Adjuvant radiotherapy following radical prostatectomy for prostate cancer
• Allopurinol for chronic prostatitis
• Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults
• Alpha-blockers as medical expulsive therapy for ureteral stones
• Alvimopan for recovery of bowel function after radical cystectomy
• Antibiotic prophylaxis for transrectal prostate biopsy
• Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
• Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy
• Antimicrobial therapy for chronic bacterial prostatitis
• Apomorphine for the treatment of erectile dysfunction
• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
• Beta-sitosterols for benign prostatic hyperplasia
• Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction
• Bisphosphonates for advanced prostate cancer
• Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis
• Blue versus white light for transurethral resection of non-muscle invasive bladder cancer
• Chemoprevention agents for prostate cancer
• Chemotherapy for hormone-refractory prostate cancer
• Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions
• Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia
• Cytoreductive nephrectomy in metastatic renal cell carcinoma
• Degarelix for treating advanced hormone-sensitive prostate cancer
• Desmopressin for treating nocturia in men
• Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer
• Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer
• En bloc versus standard transurethral resection of bladder tumors for non-muscle-invasive bladder cancer patients
• En-bloc resection versus conventional transurethral resection for patients with non-muscle-invasive bladder cancer
• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
• Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones
• Finasteride for benign prostatic hyperplasia
• First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
• Gemcitabine for unresectable, locally advanced or metastatic bladder cancer
• Ginseng for erectile dysfunction
• Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
• Hypofractionation for clinically localized prostate cancer
• Image-guided percutaneous renal core biopsy of small renal masses to diagnose renal cancer
• Immunotherapy for advanced or metastatic urothelial carcinoma
• Immunotherapy for metastatic renal cell carcinoma
• Intermittent versus continuous androgen suppression for prostatic cancer
• Interventions for chronic abacterial prostatitis
• Interventions for treating chronic prostatitis/chronic pelvic pain syndrome
• Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer
• Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
• Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer
• Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer
• Intravesical electromotive drug administration for non-muscle invasive bladder cancer
• Intravesical gemcitabine for non-muscle invasive bladder cancer
• Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis
• Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer
• Laser prostatectomy for benign prostatic obstruction
• Low-dose rate brachytherapy for men with localized prostate cancer
• Low-intensity shockwave therapy for erectile dysfunction
• Lycopene for the prevention of prostate cancer
• Maximal androgen blockade for advanced prostate cancer
• Medical and dietary interventions for preventing recurrent urinary stones in children
• Medical and surgical interventions for the treatment of urinary stones in children
• Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis
• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
• Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer
• Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
• Neo-adjuvant chemotherapy for invasive bladder cancer
• Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
• Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
• Non-surgical therapies for Peyronie's disease
• Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy
• Partial nephrectomy versus radical nephrectomy for clinical localised renal masses
• Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review
• Penile rehabilitation for postprostatectomy erectile dysfunction
• Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults
• Perioperative nutrition for the treatment of bladder cancer by radical cystectomy
• Perioperative systemic chemo-immunotherapy for upper urinary tract urothelial carcinoma
• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
• Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction
• Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer
• Prediction of disease specific and overall survival in men with prostate cancer using the Decipher assay
• Pregabalin for chronic prostatitis
• Primary cryotherapy for localised or locally advanced prostate cancer
• Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer
• Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
• Psychosocial interventions for erectile dysfunction
• Psychosocial interventions for men with prostate cancer
• Psychosocial interventions for premature ejaculation
• Pygeum africanum for benign prostatic hyperplasia
• Radical prostatectomy versus deferred treatment for localised prostate cancer
• Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
• Robotic versus open radical cystectomy for bladder cancer in adults
• Screening for prostate cancer
• Screening for testicular cancer
• Selective serotonin re-uptake inhibitors for premature ejaculation in adult men
• Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement
• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
• Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
• Surgery versus non-surgical management for unilateral ureteric-pelvic junction obstruction in newborns and infants less than two years of age
• Surgery versus radiotherapy for muscle invasive bladder cancer
• Surgical management for upper urinary tract transitional cell carcinoma
• Targeted therapy for advanced renal cell carcinoma
• Targeted therapy for metastatic renal cell carcinoma
• Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer
• Topical corticosteroids for treating phimosis in boys
• Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones
• Tranexamic acid for percutaneous nephrolithotomy
• Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
• Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi
• Ureteroscopic thulium versus holmium laser fragmentation for renal and ureteral stones in adults
• Water for preventing urinary stones

• Benign Prostatic Hyperplasia/Obstruction (Hypertrophy, Prostatic Hyperplasia) (26)
  • Screening for Benign Prostatic Hyperplasia (0)
    • Urodynamics (0)
  • Treatment of Benign Prostatic Hyperplasia (25)
    • Dietary/Lifestyle (0)
    • Surgical (2)
      • Prostatectomy (0)
      • Transurethral resection of the prostate (TURP) (2)
        • Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
        • Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction
      • Transvesical prostatectomy (TVP) (0)
    • Pharmacologic/Medical Therapies (14)
      • Alpha-blockers/Alpha-1 adrenoceptors/Alpha antagonists/5-alpha reductase inhibitors (6)
        • Alfuzosin (1)
          • Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
        • Doxazosin (1)
          • Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
        • Finasteride (0)
        • Naftopidil (2)
          • Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
          • Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
        • Prazosin (0)
        • Tamsulosin (1)
          • Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
        • Terazosin (1)
          • Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
      • Androgen Suppression (3)
        • Gonadotropin-releasing hormone agonists (0)
        • Antiandrogens (0)
        • 5 Alpha-reductase inhibitors (3)
          • 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
          • Finasteride for benign prostatic hyperplasia
          • Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
        • Combined androgen suppression and alpha-blockade (0)
      • Anticholinergics (1)
        • Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
      • Desmopressin (1)
        • Desmopressin for treating nocturia in men
      • Indoles (0)
      • Meparticin (0)
      • Phytotherapies/Plant extracts (3)
        • Pygeum africanum for benign prostatic hyperplasia
        • Beta-sitosterols for benign prostatic hyperplasia
        • Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement
    • Minimally Invasive Procedures (9)
      • Acupuncture (0)
      • Balloon dilation (0)
      • Laser prostatectomy (4)
        • Enucleation (1)
          • Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
        • Visual laser ablation of the prostate (VLAP) (1)
          • Laser prostatectomy for benign prostatic obstruction
        • Endoscopic laser ablation of the prostate (ELAP) (1)
          • Laser prostatectomy for benign prostatic obstruction
        • Hybrid lasers (1)
          • Laser prostatectomy for benign prostatic obstruction
        • Transuretal ultrasound-guided (TULIP) (0)
      • Microwave/Thermo Therapies (1)
        • Transurethral microwave therapy (TUMT) (1)
          • Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
        • Transrectal hyperthermia (TRH) (0)
        • Transurethral electroresection (TUEP) (0)
      • Miscellaneous (3)
        • Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia
        • Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis
        • Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
      • Transrectal High-Intensity Focused Ultrasound Therapy (0)
      • Transrectal Needle Ablation of the Prostate (0)
      • Mechanical (1)
        • Devices/stents (1)
          • Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
        • Catheters (0)
        • Artificial sphincters (0)
  • Rehabilitation/Management of Benign Prostatic Hyperplasia (1)
    • Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction
• Diagnostic test accuracy (1)
  • Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer
• Miscellaneous (13)
  • Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults
  • Alpha-blockers as medical expulsive therapy for ureteral stones
  • Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy
  • Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions
  • Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones
  • Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults
  • Water for preventing urinary stones
  • Medical and surgical interventions for the treatment of urinary stones in children
  • Medical and dietary interventions for preventing recurrent urinary stones in children
  • Non-surgical therapies for Peyronie's disease
  • Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
  • Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi
  • Surgery versus non-surgical management for unilateral ureteric-pelvic junction obstruction in newborns and infants less than two years of age
• Premature ejaculation (PE) (2)
  • Psychosocial interventions for premature ejaculation
  • Selective serotonin re-uptake inhibitors for premature ejaculation in adult men
• Prostatitis/Prostatitis Syndromes and Prostatodynia (10)
  • Treatment of Acute Bacterial Prostatitis (0)
    • Antibiotics (0)
      • Short Course versus Long Course (0)
    • Suppressive (0)
    • Dietary and Lifestyle (0)
  • Treatment of Chronic Bacterial Prostatitis (2)
    • Alternative therapies (1)
      • Pregabalin for chronic prostatitis
    • Antibiotics (0)
      • Short Course versus Long Course (0)
    • Suppressive (1)
      • Antimicrobial therapy for chronic bacterial prostatitis
    • Dietary and Lifestyle (0)
  • Treatment of Acute/Chronic Abacterial (Nonbacterial) Prostatitis/Chronic Pelvic Pain Syndrome (8)
    • 5-alpha reductase inhibitors (0)
    • Antibiotics (4)
      • Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
      • Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
      • Interventions for treating chronic prostatitis/chronic pelvic pain syndrome
      • Interventions for chronic abacterial prostatitis
    • Diet, Exercise and Lifestyle (0)
    • Allopurinol (2)
      • Allopurinol for chronic prostatitis
      • Interventions for chronic abacterial prostatitis
    • Alpha-blockers (1)
      • Interventions for chronic abacterial prostatitis
    • Microwave Therapy (1)
      • Interventions for chronic abacterial prostatitis
    • Pain Management (0)
  • Treatment of Prostatodynia (0)
    • Diet (0)
    • Anti-inflammatory Drugs (0)
    • Muscle Relaxants (0)
    • Sitz-baths (0)
• Prostate Cancer (Malignancy, Neoplasm) (28)
  • Cryotherapy (1)
    • Primary cryotherapy for localised or locally advanced prostate cancer
  • Immunotherapy (0)
  • Laparoscopic prostatectomy (1)
    • Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
  • Lymph Node Dissection (0)
  • Prevention of Prostate Cancer (4)
    • Diet (1)
      • Fat modified (0)
      • Antioxidants (1)
        • Lycopene for the prevention of prostate cancer
    • Pharmacologic/Medical (3)
      • 5-alpha-reductase inhibitors (1)
        • 5-alpha-reductase inhibitors for prostate cancer prevention
      • Finasteride (0)
      • Hormones (1)
        • Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer
      • Other (1)
        • Chemoprevention agents for prostate cancer
    • Surgery (0)
  • Prognostic markers (1)
    • Prediction of disease specific and overall survival in men with prostate cancer using the Decipher assay
  • Radical prostatectomy (RP) (3)
    • Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer
    • Radical prostatectomy versus deferred treatment for localised prostate cancer
    • Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer
  • Risk Stratification Tools (0)
  • Screening for Prostate Cancer (1)
    • Screening for prostate cancer
  • Rehabilitation/Management of Prostate Cancer (17)
    • Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
    • Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
    • Antibiotic prophylaxis for transrectal prostate biopsy
    • Bisphosphonates for advanced prostate cancer
    • Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis
    • Chemotherapy for hormone-refractory prostate cancer
    • Degarelix for treating advanced hormone-sensitive prostate cancer
    • Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer
    • Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer
    • Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy
    • Low-dose rate brachytherapy for men with localized prostate cancer
    • Maximal androgen blockade for advanced prostate cancer
    • Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
    • Psychosocial interventions for men with prostate cancer
    • Adjuvant radiotherapy following radical prostatectomy for prostate cancer
    • Intermittent versus continuous androgen suppression for prostatic cancer
    • Hypofractionation for clinically localized prostate cancer
• Urothelial carcinoma (Malignancy, Neoplasia): [Superficial, muscle-invasive, metastatic} (26)
  • Diet/nutrition (1)
    • Perioperative nutrition for the treatment of bladder cancer by radical cystectomy
  • Treatment of Superficial Bladder Cancer (14)
    • Bacillus Calmette Guerin (BCG) (5)
      • Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer
      • Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
      • Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis
      • Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer
      • Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer
    • Chemotherapy (2)
      • Intravesical gemcitabine for non-muscle invasive bladder cancer
      • Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis
    • Doxorubicin (0)
    • Etoglucid (0)
    • Laser Nd: YAG (0)
    • Mitomycin C (2)
      • Intravesical electromotive drug administration for non-muscle invasive bladder cancer
      • Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis
    • Photodynamic Therapy (Hematoporphyrin Derivative (HpD) (0)
    • Surgery (4)
      • Blue versus white light for transurethral resection of non-muscle invasive bladder cancer
      • Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer
      • En bloc versus standard transurethral resection of bladder tumors for non-muscle-invasive bladder cancer patients
      • En-bloc resection versus conventional transurethral resection for patients with non-muscle-invasive bladder cancer
    • Thiotepa (1)
      • Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis
  • Treatment of Muscle-invasive Bladder Cancer (7)
    • Adjuvant therapy (1)
      • Adjuvant chemotherapy for invasive bladder cancer (individual patient data)
    • Surgery (4)
      • Alvimopan for recovery of bowel function after radical cystectomy
      • Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
      • Surgery versus radiotherapy for muscle invasive bladder cancer
      • Robotic versus open radical cystectomy for bladder cancer in adults
    • Radiotherapy (2)
      • Neo-adjuvant chemotherapy for invasive bladder cancer
      • Surgery versus radiotherapy for muscle invasive bladder cancer
  • Treatment of Metastatic Bladder Cancer (3)
    • Chemotherapy (To include combination programs) (2)
      • Cisplatin (0)
      • Carboplatin (0)
      • Gemcitabine (1)
        • Gemcitabine for unresectable, locally advanced or metastatic bladder cancer
      • Iproplatin (0)
      • Methotrexate (0)
      • Doxorubicin (0)
      • Other (1)
        • Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review
      • Vinblastine (0)
      • Cyclophosphamide (0)
      • 5-Fluorouracil (0)
      • Mitomycin C (0)
      • Gallium nitrate (0)
    • Immunotherapy (1)
      • Immunotherapy for advanced or metastatic urothelial carcinoma
  • Upper tract urothelial carcinoma (1)
    • Perioperative systemic chemo-immunotherapy for upper urinary tract urothelial carcinoma
• Renal Cancer (Malignancy, Neoplasia): Renal pelvis and ureteral tumors, renal cell carcinoma (7)
  • Treatment of Renal Pelvis and Ureteral Tumors (0)
    • Surgery (0)
      • Nephrourecterectomy (0)
    • Adjuvant Therapy (0)
      • Radiation Therapy (0)
      • Chemotherapy (0)
        • Cisplatin (0)
  • Treatment of Renal Cell Carcinoma (7)
    • Miscellaneous (2)
      • Image-guided percutaneous renal core biopsy of small renal masses to diagnose renal cancer
      • First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
    • Surgery (2)
      • Cytoreductive nephrectomy in metastatic renal cell carcinoma
      • Partial nephrectomy versus radical nephrectomy for clinical localised renal masses
    • Radiation Therapy (0)
    • Hormonal Therapy (0)
      • Progesterone (0)
    • Chemotherapy (0)
      • Vinblastine (0)
      • Floxuridine (FUDR) (0)
    • Immunotherapy (3)
      • Active-specific (0)
      • Ethylchlorformate (0)
      • Dimethyldioctadecylammonium bromide (DDA) (0)
      • Active-nonspecific (2)
        • Targeted therapy for advanced renal cell carcinoma
        • Targeted therapy for metastatic renal cell carcinoma
      • Bacillus Calmette Guérin (BCG) (0)
      • Corynebacterium parvum (0)
      • Interferons (0)
      • Interleukin-2 (1)
        • Immunotherapy for metastatic renal cell carcinoma
• Other Urologic Cancers (Testicular, Penile, Urethral) (3)
  • Testicular Cancer (Malignancy, Neoplasia): [nonseminoma, seminoma, disseminated testicular] (1)
    • Screening (1)
      • Screening for testicular cancer
    • Treatment of Nonseminoma (0)
      • Active Surveillance (0)
      • Adjuvant Therapy (0)
      • Retroperitoneal Lymph Node Dissection (0)
    • Treatment of Seminoma (0)
      • Surgery (0)
        • Radical Orchiectomy (0)
      • Radiation Therapy (0)
      • Chemotherapy (0)
    • Treatment of Disseminated Testicular Cancer (0)
      • Combination Chemotherapy (0)
        • Cisplatin, Bleomycin, Vinblastine (PVD) (0)
        • Cyclophosphamide, Bleomycin, Dactinomycin, Vinblastine (0)
        • Cisplatin (VAB-6) (0)
        • Cisplatin, Etoposide, Bleomycin (PEB) (0)
        • Cisplatin, Ifosfamide, Mesna, Etoposide (VIP) (0)
      • Surgical Management after Initial Chemotherapy (0)
      • Salvage Therapy (0)
  • Penile Cancer (Malignancy, Neoplasia) (0)
    • Treatment of Penile Cancer (0)
      • Surgery (0)
      • Active Surveillance (0)
      • Chemotherapy (0)
        • 5-Fluorouracil (0)
        • Cisplatin (0)
        • Bleomycin (0)
        • Methotrexate (0)
      • Radiotherapy (including adjuvant) (0)
      • Nd:YAG Laser (0)
  • Urethral Cancer (Malignancy, Neoplasia) (2)
    • Treatment of Urethral Cancer (2)
      • Surgery (Urinary diversion) (1)
        • Surgical management for upper urinary tract transitional cell carcinoma
      • Laser Ablation (0)
      • Radiation Therapy (0)
      • Chemotherapy (1)
        • Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
• Erectile Dysfunction (5)
  • Treatment of Erectile Dysfunction (5)
    • Mechanical Devices (0)
      • Vacuum Constriction (0)
    • Miscellaneous (2)
      • Low-intensity shockwave therapy for erectile dysfunction
      • Penile rehabilitation for postprostatectomy erectile dysfunction
    • Phytotherapies (1)
      • Ginseng for erectile dysfunction
    • Psychosocial interventions (1)
      • Psychosocial interventions for erectile dysfunction
    • Surgery (0)
      • Penile Prosthesis Implantation (0)
    • Pharmacologic/Medical Therapies (1)
      • Vasoactive Drug Injection Therapy (0)
        • Alprostadil, PGE1 (0)
        • Papaverine (0)
      • Intraurethral Drug Therapy (0)
        • Alprostadil (0)
      • Oral Drug Therapy (1)
        • Sildenafil (0)
        • Vardenafil (0)
        • Yohimbine (0)
        • Phentolamine (0)
        • Trazodone (0)
        • Apomorphine (1)
          • Apomorphine for the treatment of erectile dysfunction
      • Transdermal/Topical Applications (0)